Literature DB >> 9757314

Ki-67 antigen expression as a prognostic factor in primary and recurrent astrocytomas.

S Eneström1, L Vavruch, B Frånlund, B Nordenskjöld.   

Abstract

BACKGROUND AND
PURPOSE: Histological grading is widely used to evaluate the prognosis for patients with astrocytic tumors. Many complimentary methods have been introduced, such as proliferation markers in order to better assess the proliferative potential of these gliomas.
METHODS: Archival, paraffin embedded specimens of recurrent astrocytic tumors of varying grades from 22 patients were examined using antibodies against Ki-67 (MIB-1). Labeling indices (LI) were analyzed at the first and second operations and compared with tumor grades, age of the patients and the time between the operations as well as the survival time.
RESULTS: There was a progression of malignancy between the operations. Dividing Ki-67 labeling indices in < or = 10% vs. > 10% significantly separated parameters such as the time between the first operation and relapse as well as the cumulative proportion of survival. The proliferation fraction was an independent prognostic factor.
CONCLUSION: Assessment of Ki-67 LI is highly recommended in addition to histology in evaluation of the malignancy potential of astrocytic tumors.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9757314

Source DB:  PubMed          Journal:  Neurochirurgie        ISSN: 0028-3770            Impact factor:   1.553


  15 in total

1.  Comparison of Ki-67 equivalent antibodies.

Authors:  C F Lindboe; S H Torp
Journal:  J Clin Pathol       Date:  2002-06       Impact factor: 3.411

2.  HMGA1 expression in human gliomas and its correlation with tumor proliferation, invasion and angiogenesis.

Authors:  Bo Pang; Haitao Fan; Ian Y Zhang; Bin Liu; Bin Feng; Lei Meng; Rui Zhang; Sam Sadeghi; Hua Guo; Qi Pang
Journal:  J Neurooncol       Date:  2011-10-08       Impact factor: 4.130

3.  Clinicopathological features, MIB-1 labeling index and apoptotic index in recurrent astrocytic tumors.

Authors:  A M Ralte; M C Sharma; A K Karak; V S Mehta; C Sarkar
Journal:  Pathol Oncol Res       Date:  2001       Impact factor: 3.201

Review 4.  The clinical value of Ki-67/MIB-1 labeling index in human astrocytomas.

Authors:  Anne Linn Johannessen; Sverre Helge Torp
Journal:  Pathol Oncol Res       Date:  2006-09-23       Impact factor: 3.201

5.  Prognostic significance of the immunohistochemical index of survivin in glioma: a comparative study with the MIB-1 index.

Authors:  Masaki Uematsu; Ikuroh Ohsawa; Toshiyuki Aokage; Kiyomi Nishimaki; Kouji Matsumoto; Hiroshi Takahashi; Sadamitsu Asoh; Akira Teramoto; Shigeo Ohta
Journal:  J Neurooncol       Date:  2005-05       Impact factor: 4.130

6.  Expression of hepatocyte growth factor and its receptor c-Met in human pituitary adenomas.

Authors:  Xian-Zeng Hou; Wei Liu; Hai-Tao Fan; Bin Liu; Bo Pang; Tao Xin; Shang-Chen Xu; Qi Pang
Journal:  Neuro Oncol       Date:  2010-03-03       Impact factor: 12.300

7.  Ki-67 labeling is correlated with the time to recurrence in primary glioblastomas.

Authors:  Roland Schröder; Klaus D Feisel; Ralf-Ingo Ernestus
Journal:  J Neurooncol       Date:  2002-01       Impact factor: 4.130

8.  Intense p53 staining is a valuable prognostic indicator for poor prognosis in medulloblastoma/central nervous system primitive neuroectodermal tumors.

Authors:  R T Woodburn; B Azzarelli; J F Montebello; I E Goss
Journal:  J Neurooncol       Date:  2001-03       Impact factor: 4.130

9.  The expression level of sphingosine-1-phosphate receptor type 1 is related to MIB-1 labeling index and predicts survival of glioblastoma patients.

Authors:  Yuya Yoshida; Mitsutoshi Nakada; Tomoya Harada; Shingo Tanaka; Takuya Furuta; Yasuhiko Hayashi; Daisuke Kita; Naoyuki Uchiyama; Yutaka Hayashi; Jun-ichiro Hamada
Journal:  J Neurooncol       Date:  2009-11-25       Impact factor: 4.130

10.  p53, mdm2, EGFR, and msh2 expression in paired initial and recurrent glioblastoma multiforme.

Authors:  A M Stark; P Witzel; R J Strege; H-H Hugo; H M Mehdorn
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-06       Impact factor: 10.154

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.